Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

TAMAR F BRIONEZ

Allopathic & Osteopathic Physicians Internal Medicine Rheumatology

NPI
1457407041
CMS profile
20898
Location
THE WOODLANDS, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$26,078.46

150 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

By paying entity

PY2021 · entire year · sorted by reported total

Page 3 of 3; records 101–150 of 150 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

TAMAR F BRIONEZ

NPI 1457407041 · CMS profile ID 20898

Allopathic & Osteopathic Physicians / Internal Medicine / Rheumatology

THE WOODLANDS, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 3; records 101–150 of 150 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1457407041?year=2021&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
TAMAR F BRIONEZ, NPI 1457407041, CMS profile ID 20898. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–150 of 150 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1457407041?year=2021&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). TAMAR F BRIONEZ, NPI 1457407041, CMS profile ID 20898. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–150 of 150 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1457407041?year=2021&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
TAMAR F BRIONEZ, NPI 1457407041, CMS profile ID 20898, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 3; records 101–150 of 150 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1457407041?year=2021&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

150 matching records · $26,078.46 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 150 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–150 of 150.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Teva Pharmaceuticals USA, Inc. $17.8804/26/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 839655785 CMS
Lilly USA, LLC $23.0504/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818764389 CMS
Novartis Pharmaceuticals Corporation $19.1404/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 812618393 CMS
AbbVie Inc. $28.0504/20/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794149899 CMS
Genentech USA, Inc. $24.1604/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 835983139 CMS
AbbVie Inc. $26.7304/13/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794149895 CMS
UCB, Inc. $23.1004/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 807340005 CMS
AbbVie Inc. $22.7804/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794149891 CMS
E.R. Squibb & Sons, L.L.C. $18.0804/07/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783406623 CMS
PFIZER INC. $27.8904/06/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 832926835 CMS
Radius Health, Inc. $20.7404/05/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 830707589 CMS
GlaxoSmithKline, LLC. $19.6704/02/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 802291151 CMS
Mallinckrodt Hospital Products Inc. $14.0203/30/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845348277 CMS
Amgen Inc. $14.2803/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825822157 CMS
Janssen Biotech, Inc. $12.6703/24/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788260421 CMS
Lilly USA, LLC $17.2003/24/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818683459 CMS
Amgen Inc. $16.1703/23/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825822225 CMS
Horizon Therapeutics plc $21.3003/17/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 797084841 CMS
Novartis Pharmaceuticals Corporation $20.4003/17/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 812618391 CMS
E.R. Squibb & Sons, L.L.C. $17.4203/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783406615 CMS
AbbVie Inc. $26.4003/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794149887 CMS
PFIZER INC. $24.5303/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 832956847 CMS
Amgen Inc. $18.3803/02/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825822221 CMS
Hikma Pharmaceuticals USA $15.3902/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 808537469 CMS
Janssen Biotech, Inc. $17.6102/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788260411 CMS
UCB, Inc. $9.0202/23/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 807300707 CMS
UCB, Inc. $8.1002/23/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 807327603 CMS
Lilly USA, LLC $15.5202/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818762769 CMS
AbbVie Inc. $24.7002/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794149883 CMS
PFIZER INC. $22.1202/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 832953217 CMS
AbbVie Inc. $18.5602/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794149879 CMS
E.R. Squibb & Sons, L.L.C. $17.2402/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783406601 CMS
UCB, Inc. $19.5402/04/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 807308023 CMS
Mallinckrodt Hospital Products Inc. $18.9402/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845348275 CMS
UCB, Inc. $15.1602/02/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 807319483 CMS
E.R. Squibb & Sons, L.L.C. $15.4002/01/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783406607 CMS
GlaxoSmithKline, LLC. $2,100.0001/27/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 801670845 CMS
Amgen Inc. $15.6301/26/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825822153 CMS
Janssen Biotech, Inc. $13.1001/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788260397 CMS
UCB, Inc. $2.0801/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 807308163 CMS
Lilly USA, LLC $12.1801/20/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818764391 CMS
UCB, Inc. $4.3901/20/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 807308135 CMS
UCB, Inc. $6.9801/20/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 807308139 CMS
Novartis Pharmaceuticals Corporation $17.6601/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 812618389 CMS
PFIZER INC. $2,220.0001/15/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 832929827 CMS
PFIZER INC. $16.0201/13/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 832930741 CMS
AbbVie Inc. $21.0301/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794149875 CMS
Amgen Inc. $11.8901/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825822177 CMS
Amgen Inc. $14.5101/05/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825822217 CMS
UCB, Inc. $10.4701/05/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 807297925 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $44,286.28 243
PY2020 $23,602.46 153
PY2021 $26,078.46 150
PY2022 $22,204.69 141
PY2023 $11,322.14 88
PY2024 $11,671.93 91
PY2025 $11,355.36 110

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $1,217,311.76 78
PY2024 Recipient $36,664.58 2
PY2024 Principal investigator $1,040,077.60 67
PY2023 Principal investigator $583,130.23 92
PY2022 Principal investigator $859,473.48 257
PY2021 Principal investigator $616,368.11 128
PY2020 Recipient $2,603.72 4
PY2020 Principal investigator $574,505.51 143
PY2019 Recipient $13,017.22 5
PY2019 Principal investigator $143,696.84 23

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

78 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Janssen Research & Development, LLC $6,530.00 12/22/2025 Non-covered Recipient Entity
ARH RESEARCH LLC
Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent No dispute reported 06/30/2026 1175418777
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $5,765.27 12/19/2025 Non-covered Recipient Entity
ADVANCED RHEUMATOLOGY
A Multi-Center, Randomized, Double-Blind, and Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects with Active Psoriatic Arthritis Stratified by Prior Biologic Use (LATITUDE-PsA-3002 No dispute reported 06/30/2026 1223290032
Principal investigator 1 Amgen Inc. $150.00 12/05/2025 Non-covered Recipient Entity
ARH RESEARCH LLC
A Multicenter, Open-Label, Long-term, Extension Study to Evaluate the Safety and Tolerability of Dazodalibep in Participants With Sjgren's Syndrome (SS) No dispute reported 06/30/2026 1246639177
Principal investigator 1 ABBVIE INC. $6,071.24 12/04/2025 Non-covered Recipient Entity
DR TAMAR F BRIONEZ MD PA
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy No dispute reported 06/30/2026 1202528702
Principal investigator 1 Novartis Pharmaceuticals Corporation $20.00 12/01/2025 Non-covered Recipient Entity
ADVANCED RHEUMATOLOGY OF HOUSTON
A Randomized, Parallel Group, Double Blind, Placebo Controlled Multicenter Phase III Trial to Investigate the Efficacy and Safety of Secukinumab 300 mg Administered Subcutaneously Versus Placebo, in Combination With Glucocorticoid Taper Regimen, in Patien No dispute reported 06/30/2026 1190303591
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,567.27 12/01/2025 Non-covered Recipient Entity
ADVANCED RHEUMATOLOGY
A Multi-Center, Randomized, Double-Blind, and Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects with Active Psoriatic Arthritis Stratified by Prior Biologic Use (LATITUDE-PsA-3002 No dispute reported 06/30/2026 1223289124
Principal investigator 1 Novartis Pharmaceuticals Corporation $17.12 11/15/2025 Non-covered Recipient Entity
ADVANCED RHEUMATOLOGY OF HOUSTON
A Randomized, Parallel-group, Double-blind, Placebo-controlled, Multicenter Phase III Trial to Evaluate Efficacy and Safety of Secukinumab Administered Subcutaneously Versus Placebo, in Combination With a Glucocorticoid Taper Regimen, in Patients With Pol No dispute reported 06/30/2026 1190303585
Principal investigator 1 ABBVIE INC. $650.00 11/05/2025 Non-covered Recipient Entity
ADVANCED RHEUMATOLOGY OF HOUSTON
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202522407
Principal investigator 1 ABBVIE INC. $2,203.38 11/04/2025 Non-covered Recipient Entity
DR TAMAR F BRIONEZ MD PA
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy No dispute reported 06/30/2026 1202520681
Principal investigator 1 Janssen Research & Development, LLC $1,186.00 10/31/2025 Non-covered Recipient Entity
ARH RESEARCH LLC
Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent No dispute reported 06/30/2026 1175418822
Principal investigator 1 ABBVIE INC. $1,300.00 10/28/2025 Non-covered Recipient Entity
ADVANCED RHEUMATOLOGY OF HOUSTON
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202518837
Principal investigator 1 ABBVIE INC. $36.92 10/24/2025 Non-covered Recipient Entity
ADVANCED RHEUMATOLOGY OF HOUSTON
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202518495
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,937.27 10/15/2025 Non-covered Recipient Entity
ADVANCED RHEUMATOLOGY
A Multi-Center, Randomized, Double-Blind, and Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects with Active Psoriatic Arthritis Stratified by Prior Biologic Use (LATITUDE-PsA-3002 No dispute reported 06/30/2026 1223287001
Principal investigator 1 ABBVIE INC. $2,094.58 10/09/2025 Non-covered Recipient Entity
DR TAMAR F BRIONEZ MD PA
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy No dispute reported 06/30/2026 1202516207
Principal investigator 1 Novartis Pharmaceuticals Corporation $436.93 10/08/2025 Non-covered Recipient Entity
ADVANCED RHEUMATOLOGY OF HOUSTON
A Randomized, Two-period Crossover Study to Demonstrate the Comparability of Pharmacokinetics of Subcutaneous Ianalumab Between 2mL Auto-injector/2mL Pre-filled Syringe With 1 mL Pre-filled Syringe in Adult Participants With Autoimmune Disease No dispute reported 06/30/2026 1190303595
Principal investigator 1 Novartis Pharmaceuticals Corporation $493.37 10/08/2025 Non-covered Recipient Entity
ADVANCED RHEUMATOLOGY OF HOUSTON
A randomized, double-blind 2-arm NEPTUNUS extension study to assess the long-term safety and efficacy of ianalumab in patients with Sjogrens syndrome No dispute reported 06/30/2026 1190303599
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,700.00 10/08/2025 Non-covered Recipient Entity
ADVANCED RHEUMATOLOGY
A Multi-Center, Randomized, Double-Blind, and Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects with Active Psoriatic Arthritis Stratified by Prior Biologic Use (LATITUDE-PsA-3002 No dispute reported 06/30/2026 1223286515
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $5,000.00 10/08/2025 Non-covered Recipient Entity
ADVANCED RHEUMATOLOGY
A Multi-Center, Randomized, Double-Blind, and Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects with Active Psoriatic Arthritis Stratified by Prior Biologic Use (LATITUDE-PsA-3002 No dispute reported 06/30/2026 1223286517
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,500.00 10/08/2025 Non-covered Recipient Entity
ADVANCED RHEUMATOLOGY
A Multi-Center, Randomized, Double-Blind, and Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects with Active Psoriatic Arthritis Stratified by Prior Biologic Use (LATITUDE-PsA-3002 No dispute reported 06/30/2026 1223286519
Principal investigator 1 ABBVIE INC. $350.00 10/07/2025 Non-covered Recipient Entity
DR TAMAR F BRIONEZ MD PA
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy No dispute reported 06/30/2026 1202513469
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $550.00 10/03/2025 Non-covered Recipient Entity
ADVANCED RHEUMATOLOGY
A Multi-Center, Randomized, Double-Blind, and Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects with Active Psoriatic Arthritis Stratified by Prior Biologic Use (LATITUDE-PsA-3002 No dispute reported 06/30/2026 1223286329
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $650.00 10/03/2025 Non-covered Recipient Entity
ADVANCED RHEUMATOLOGY
A Multi-Center, Randomized, Double-Blind, and Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects with Active Psoriatic Arthritis Stratified by Prior Biologic Use (LATITUDE-PsA-3002 No dispute reported 06/30/2026 1223286331
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $6,024.62 10/01/2025 Non-covered Recipient Entity
ADVANCED RHEUMATOLOGY
A Multi-Center, Randomized, Double-Blind, and Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects with Active Psoriatic Arthritis Stratified by Prior Biologic Use (LATITUDE-PsA-3002 No dispute reported 06/30/2026 1223286155
Principal investigator 1 Eli Lilly and Company $111.45 09/09/2025 Non-covered Recipient Entity
TAMAR BRIONEZ
A PHASE 3 STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ORFORGLIPRON ONCE DAILY IN PARTICIPANTS WHO HAVE OBESITY OR OVERWEIGHT AND OSTEOARTHRITIS OF THE KNEE: A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL-ARM, PLACEBO-CONTROLLED TRIAL No dispute reported 06/30/2026 1187892322
Principal investigator 1 ABBVIE INC. $4,893.59 09/03/2025 Non-covered Recipient Entity
DR TAMAR F BRIONEZ MD PA
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy No dispute reported 06/30/2026 1202507537
Principal investigator 1 Janssen Research & Development, LLC $2,282.00 09/01/2025 Non-covered Recipient Entity
ARH RESEARCH LLC
Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent No dispute reported 06/30/2026 1175418802
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $9,368.94 08/20/2025 Non-covered Recipient Entity
ADVANCED RHEUMATOLOGY PC
A Multi-Center, Randomized, Double-Blind, and Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects with Active Psoriatic Arthritis Stratified by Prior Biologic Use (LATITUDE-PsA-3002 No dispute reported 06/30/2026 1223284389
Principal investigator 1 Otsuka Pharmaceutical Development & Commercialization, Inc. $29,137.95 08/15/2025 Non-covered Recipient Entity
ARH RESEARCH LLC
PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND,PLACEBO-CONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF SIBEPRENLIMAB ADMINISTERED SUBCUTANEOUSLY IN SUBJECTS WITH ACTIVE PRIMARY SJGRENS SYNDROME (PSS) No dispute reported 06/30/2026 1225336029
Principal investigator 1 Janssen Research & Development, LLC $4,395.00 08/11/2025 Non-covered Recipient Entity
ARH RESEARCH LLC
Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent No dispute reported 06/30/2026 1175418766
Principal investigator 1 ABBVIE INC. $500.00 08/07/2025 Non-covered Recipient Entity
ADVANCED RHEUMATOLOGY OF HOUSTON
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202503897
Principal investigator 1 ABBVIE INC. $1,188.70 08/05/2025 Non-covered Recipient Entity
DR TAMAR F BRIONEZ MD PA
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy No dispute reported 06/30/2026 1202501750
Principal investigator 1 ABBVIE INC. $2,226.99 08/01/2025 Non-covered Recipient Entity
DR TAMAR F BRIONEZ MD PA
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy No dispute reported 06/30/2026 1202500830
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $15,000.00 07/23/2025 Non-covered Recipient Entity
ADVANCED RHEUMATOLOGY PC
A Multi-Center, Randomized, Double-Blind, and Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects with Active Psoriatic Arthritis Stratified by Prior Biologic Use (LATITUDE-PsA-3002 No dispute reported 06/30/2026 1223283010
Principal investigator 1 Amgen Inc. $32,363.77 07/16/2025 Non-covered Recipient Entity
ADVANCED RHEUMATOLOGY OF HOUSTON
A Multicenter, Open-Label, Long-term, Extension Study to Evaluate the Safety and Tolerability of Dazodalibep in Participants With Sjgren's Syndrome (SS) No dispute reported 06/30/2026 1246638871
Principal investigator 1 Janssen Research & Development, LLC $1,230.00 07/07/2025 Non-covered Recipient Entity
ARH RESEARCH LLC
Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent No dispute reported 06/30/2026 1175418756
Principal investigator 1 ABBVIE INC. $4,338.46 07/02/2025 Non-covered Recipient Entity
DR TAMAR F BRIONEZ MD PA
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy No dispute reported 06/30/2026 1202494237
Principal investigator 1 ABBVIE INC. $3,500.00 07/02/2025 Non-covered Recipient Entity
ADVANCED RHEUMATOLOGY OF HOUSTON
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202494361
Principal investigator 1 ABBVIE INC. $1,162.96 07/02/2025 Non-covered Recipient Entity
DR TAMAR F BRIONEZ MD PA
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy No dispute reported 06/30/2026 1202494363
Principal investigator 1 ABBVIE INC. $50.11 07/02/2025 Non-covered Recipient Entity
ADVANCED RHEUMATOLOGY OF HOUSTON
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202494365
Principal investigator 1 ABBVIE INC. $25.60 07/02/2025 Non-covered Recipient Entity
DR TAMAR F BRIONEZ MD PA
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy No dispute reported 06/30/2026 1202494367
Principal investigator 1 GlaxoSmithKline, LLC. $75.00 06/26/2025 Non-covered Recipient Entity
ADVANCED RHEUMATOLOGY OF HOUSTON
A 5-YEAR PROSPECTIVE OBSERVATIONAL REGISTRY TO ASSESS ADVERSE EVENTS O No dispute reported 06/30/2026 1192115379
Principal investigator 1 Amgen Inc. $139,782.10 06/04/2025 Non-covered Recipient Entity
ARH RESEARCH LLC
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjgren's Syndrome With Moderate-to-severe Systemic Disease Activity No dispute reported 06/30/2026 1246639179
Principal investigator 1 ABBVIE INC. $2,042.73 06/03/2025 Non-covered Recipient Entity
DR TAMAR F BRIONEZ MD PA
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy No dispute reported 06/30/2026 1202489571
Principal investigator 1 Janssen Research & Development, LLC $2,282.00 06/02/2025 Non-covered Recipient Entity
ARH RESEARCH LLC
Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent No dispute reported 06/30/2026 1175418796
Principal investigator 1 ABBVIE INC. $700.00 05/29/2025 Non-covered Recipient Entity
DR TAMAR F BRIONEZ MD PA
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy No dispute reported 06/30/2026 1202487101
Principal investigator 1 Eli Lilly and Company $13,437.00 05/27/2025 Non-covered Recipient Entity
ARH RESEARCH LLC
A PHASE 4, PROSPECTIVE, OPEN-LABEL, SINGLE-ARM STUDY TO ASSESS THE EFFECTIVENESS OF TIRZEPATIDE AFTER INITIATION OF IXEKIZUMAB IN ADULT PARTICIPANTS WITH ACTIVE PSORIATIC ARTHRITIS AND OVERWEIGHT OR OBESITY IN CLINICAL PRACTICE No dispute reported 06/30/2026 1187876885
Principal investigator 1 Janssen Research & Development, LLC $1,000.00 05/23/2025 Non-covered Recipient Entity
ARH RESEARCH LLC
Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent No dispute reported 06/30/2026 1175418790
Principal investigator 1 ABBVIE INC. $2,256.06 05/06/2025 Non-covered Recipient Entity
DR TAMAR F BRIONEZ MD PA
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy No dispute reported 06/30/2026 1202482279
Principal investigator 1 Janssen Research & Development, LLC $1,186.00 04/28/2025 Non-covered Recipient Entity
ARH RESEARCH LLC
Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent No dispute reported 06/30/2026 1175418782
Principal investigator 1 ABBVIE INC. $3,131.40 04/03/2025 Non-covered Recipient Entity
DR TAMAR F BRIONEZ MD PA
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy No dispute reported 06/30/2026 1202471152
Principal investigator 1 ABBVIE INC. $24.06 04/03/2025 Non-covered Recipient Entity
DR TAMAR F BRIONEZ MD PA
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy No dispute reported 06/30/2026 1202471156
Principal investigator 1 Janssen Research & Development, LLC $2,372.00 03/31/2025 Non-covered Recipient Entity
ARH RESEARCH LLC
Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent No dispute reported 06/30/2026 1175418772
Principal investigator 1 ABBVIE INC. $4,666.81 03/06/2025 Non-covered Recipient Entity
DR TAMAR F BRIONEZ MD PA
M16-011 - A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy No dispute reported 06/30/2026 1202456940
Principal investigator 1 Janssen Research & Development, LLC $82.00 02/17/2025 Non-covered Recipient Entity
ARH RESEARCH LLC
Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent No dispute reported 06/30/2026 1175418761
Principal investigator 1 Amgen Inc. $16,867.23 02/11/2025 Non-covered Recipient Entity
ADVANCED RHEUMATOLOGY OF HOUSTON
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjgren's Syndrome With Moderate-to-severe Systemic Disease Activity No dispute reported 06/30/2026 1246638875
Principal investigator 1 ABBVIE INC. $18.58 02/06/2025 Non-covered Recipient Entity
ADVANCED RHEUMATOLOGY OF HOUSTON
M23-700 - Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202447082
Principal investigator 1 ABBVIE INC. $2,589.93 02/05/2025 Non-covered Recipient Entity
DR TAMAR F BRIONEZ MD PA
M16-011 - A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy No dispute reported 06/30/2026 1202443927
Principal investigator 1 Novartis Pharmaceuticals Corporation $8,334.90 01/30/2025 Non-covered Recipient Entity
ARH RESEARCH LLC
A Randomized, Double-blind, Placebo Controlled, 3-arm Multicenter Phase 3 Study to Assess the Efficacy and Safety of Ianalumab in Patients With Active Sjogren's Syndrome (NEPTUNUS-2) No dispute reported 06/30/2026 1190311283
Principal investigator 1 ABBVIE INC. $34.51 01/29/2025 Non-covered Recipient Entity
DR TAMAR F BRIONEZ MD PA
M16-011 - A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy No dispute reported 06/30/2026 1202441763
Principal investigator 1 Novartis Pharmaceuticals Corporation $24,092.00 01/28/2025 Non-covered Recipient Entity
ARH RESEARCH LLC
A Randomized, Parallel-group, Double-blind, Placebo-controlled, Multicenter Phase III Trial to Evaluate Efficacy and Safety of Secukinumab Administered Subcutaneously Versus Placebo, in Combination With a Glucocorticoid Taper Regimen, in Patients With Pol No dispute reported 06/30/2026 1190311273
Principal investigator 1 Eli Lilly and Company $3,156.90 01/27/2025 Non-covered Recipient Entity
TAMAR BRIONEZ
EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH ACTIVE PSORIATIC ARTHRITIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSA) No dispute reported 06/30/2026 1187889648
Principal investigator 1 Janssen Research & Development, LLC $1,476.00 01/27/2025 Non-covered Recipient Entity
ARH RESEARCH LLC
Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent No dispute reported 06/30/2026 1175418808
Principal investigator 1 Amgen Inc. $42,018.44 01/22/2025 Non-covered Recipient Entity
ADVANCED RHEUMATOLOGY OF HOUSTON
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants with Sjgrens Syndrome With Moderate-to-Severe Symptom State No dispute reported 06/30/2026 1246638873
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $83,021.41 01/21/2025 Non-covered Recipient Entity
Advanced Rheumatology Of Houston
A Study to Assess Effectiveness and Safety of Deucravacitinib Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE) (POETYK SLE-1) No dispute reported 06/30/2026 1235999277
Principal investigator 1 Janssen Research & Development, LLC $82.00 01/20/2025 Non-covered Recipient Entity
ARH RESEARCH LLC
Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent No dispute reported 06/30/2026 1175418815
Principal investigator 1 Novartis Pharmaceuticals Corporation $27,629.75 01/16/2025 Non-covered Recipient Entity
ARH RESEARCH LLC
A Multi-center, Open-label Extension Study of Subcutaneous Secukinumab to Evaluate the Long-term Safety and Tolerability in Polymyalgia Rheumatica (PMR) No dispute reported 06/30/2026 1190311275
Principal investigator 1 Novartis Pharmaceuticals Corporation $148,097.15 01/16/2025 Non-covered Recipient Entity
ARH RESEARCH LLC
A Randomized, Two-period Crossover Study to Demonstrate the Comparability of Pharmacokinetics of Subcutaneous Ianalumab Between 2mL Auto-injector/2mL Pre-filled Syringe With 1 mL Pre-filled Syringe in Adult Participants With Autoimmune Disease No dispute reported 06/30/2026 1190311279
Principal investigator 1 Novartis Pharmaceuticals Corporation $21,795.00 01/16/2025 Non-covered Recipient Entity
ARH RESEARCH LLC
A randomized, double-blind 2-arm NEPTUNUS extension study to assess the long-term safety and efficacy of ianalumab in patients with Sjogrens syndrome No dispute reported 06/30/2026 1190311281
Principal investigator 1 Novartis Pharmaceuticals Corporation $1,408.00 01/14/2025 Non-covered Recipient Entity
ARH RESEARCH LLC
A Randomized, Parallel Group, Double Blind, Placebo Controlled Multicenter Phase III Trial to Investigate the Efficacy and Safety of Secukinumab 300 mg Administered Subcutaneously Versus Placebo, in Combination With Glucocorticoid Taper Regimen, in Patien No dispute reported 06/30/2026 1190311277
Principal investigator 1 GlaxoSmithKline, LLC. $75.00 01/10/2025 Non-covered Recipient Entity
TAMAR BRIONEZ MD PA
A 5-YEAR PROSPECTIVE OBSERVATIONAL REGISTRY TO ASSESS ADVERSE EVENTS O No dispute reported 06/30/2026 1192115373
Principal investigator 1 Novartis Pharmaceuticals Corporation $54,864.08 01/09/2025 Non-covered Recipient Entity
ADVANCED RHEUMATOLOGY OF HOUSTON
A Randomized, Two-period Crossover Study to Demonstrate the Comparability of Pharmacokinetics of Subcutaneous Ianalumab Between 2mL Auto-injector/2mL Pre-filled Syringe With 1 mL Pre-filled Syringe in Adult Participants With Autoimmune Disease No dispute reported 06/30/2026 1190303597
Principal investigator 1 Novartis Pharmaceuticals Corporation $16,373.44 01/09/2025 Non-covered Recipient Entity
ADVANCED RHEUMATOLOGY OF HOUSTON
A randomized, double-blind 2-arm NEPTUNUS extension study to assess the long-term safety and efficacy of ianalumab in patients with Sjogrens syndrome No dispute reported 06/30/2026 1190303601
Principal investigator 1 Novartis Pharmaceuticals Corporation $1,108.43 01/09/2025 Non-covered Recipient Entity
ADVANCED RHEUMATOLOGY OF HOUSTON
A Randomized, Double-blind, Placebo Controlled, 3-arm Multicenter Phase 3 Study to Assess the Efficacy and Safety of Ianalumab in Patients With Active Sjogren's Syndrome (NEPTUNUS-2) No dispute reported 06/30/2026 1190303603
Principal investigator 1 Eli Lilly and Company $146,650.00 01/07/2025 Non-covered Recipient Entity
ARH RESEARCH LLC
EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH ACTIVE PSORIATIC ARTHRITIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSA) No dispute reported 06/30/2026 1187880723
Principal investigator 1 Novartis Pharmaceuticals Corporation $23,283.52 01/07/2025 Non-covered Recipient Entity
ADVANCED RHEUMATOLOGY OF HOUSTON
A Randomized, Parallel-group, Double-blind, Placebo-controlled, Multicenter Phase III Trial to Evaluate Efficacy and Safety of Secukinumab Administered Subcutaneously Versus Placebo, in Combination With a Glucocorticoid Taper Regimen, in Patients With Pol No dispute reported 06/30/2026 1190303587
Principal investigator 1 Novartis Pharmaceuticals Corporation $244,129.76 01/06/2025 Non-covered Recipient Entity
ADVANCED RHEUMATOLOGY OF HOUSTON
A Multi-center, Open-label Extension Study of Subcutaneous Secukinumab to Evaluate the Long-term Safety and Tolerability in Polymyalgia Rheumatica (PMR) No dispute reported 06/30/2026 1190303589
Principal investigator 1 ABBVIE INC. $3,323.94 01/02/2025 Non-covered Recipient Entity
DR TAMAR F BRIONEZ MD PA
M16-011 - A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy No dispute reported 06/30/2026 1202433626
Principal investigator 1 Novartis Pharmaceuticals Corporation $9,835.14 01/01/2025 Non-covered Recipient Entity
ADVANCED RHEUMATOLOGY OF HOUSTON
A Randomized, Parallel Group, Double Blind, Placebo Controlled Multicenter Phase III Trial to Investigate the Efficacy and Safety of Secukinumab 300 mg Administered Subcutaneously Versus Placebo, in Combination With Glucocorticoid Taper Regimen, in Patien No dispute reported 06/30/2026 1190303593